Sagility Limited Reports Strong Q2 FY27 Results and Chirok Health Acquisition
Sagility Ltd · Outcome · 23 Oct 2026, 12:07 am
Sagility Limited Reports Strong Q2 FY27 Results and Chirok Health Acquisition Sagility Limited posted a 22.5% YoY rise in Q2 FY27 consolidated revenue from operations to ₹20,321 million (12.2% constant currency growth). Adjusted EBITDA rose 23.0% YoY to ₹5,353 million with margins at 26.3%, while consolidated PAT grew 13.3% YoY to ₹2,842.12 million. The company secured $40.2 million in ACV and approved an interim dividend of ₹0.15 per share (record date 30th Oct'26). Additionally, Sagility signed a definitive agreement on 21st Oct'26 to acquire US-based Chirok Health LLC for up to $32.35 million.
Original exchange filing (PDF)
More announcements from Sagility Ltd
- The Company has made grant of stock options under the Employee Stock Options and Performance Stock Units Scheme 2026 of the Company · 14 Nov 2026
- The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 02, 2026 for Sagility BV · 03 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sagility B.V. · 03 Nov 2026
- Transcript of Earnings Call held on October 22, 2026 · 29 Oct 2026
- Communication to Shareholders regarding TDS on Interim Dividend FY2026-27 · 23 Oct 2026
- Disclosure of Investor Call Recording Q2FY27 · 23 Oct 2026
- Board approves Interim dividend for FY 2026-27 · 23 Oct 2026
- Corporate Action - Record date intimation for Interim dividend FY 2026-27 · 23 Oct 2026
